A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by exceedingly high rates of metastatic progression, with the liver representing the most common site of distant spread. Here, we established a platform for multisite immune profiling of human PDAC encompassing the tumor, p...

Full description

Saved in:
Bibliographic Details
Main Authors: Elishama N. Kanu, Ashley A. Fletcher, Jiayin Bao, Ethan S. Agritelley, Julia Button, Austin M. Eckhoff, Karrie Comatas, Tao Wang, Bin-Jin Hwang, Michael E. Lidsky, Sabino Zani, Dan G. Blazer, Peter J. Allen, Zhicheng Ji, Frank J. Lowery, Sri Krishna, Nicholas D. Klemen, Daniel P. Nussbaum, Erika J. Crosby
Format: Article
Language:English
Published: Springer 2025-08-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Online Access:https://doi.org/10.1007/s00262-025-04146-5
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849226186016686080
author Elishama N. Kanu
Ashley A. Fletcher
Jiayin Bao
Ethan S. Agritelley
Julia Button
Austin M. Eckhoff
Karrie Comatas
Tao Wang
Bin-Jin Hwang
Michael E. Lidsky
Sabino Zani
Dan G. Blazer
Peter J. Allen
Zhicheng Ji
Frank J. Lowery
Sri Krishna
Nicholas D. Klemen
Daniel P. Nussbaum
Erika J. Crosby
author_facet Elishama N. Kanu
Ashley A. Fletcher
Jiayin Bao
Ethan S. Agritelley
Julia Button
Austin M. Eckhoff
Karrie Comatas
Tao Wang
Bin-Jin Hwang
Michael E. Lidsky
Sabino Zani
Dan G. Blazer
Peter J. Allen
Zhicheng Ji
Frank J. Lowery
Sri Krishna
Nicholas D. Klemen
Daniel P. Nussbaum
Erika J. Crosby
author_sort Elishama N. Kanu
collection DOAJ
description Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by exceedingly high rates of metastatic progression, with the liver representing the most common site of distant spread. Here, we established a platform for multisite immune profiling of human PDAC encompassing the tumor, peripheral circulation, and premetastatic liver, to more comprehensively study how various immune subsets might contribute to patient outcomes. Methods Tumor, liver, and blood samples were obtained from patients undergoing resection for non-metastatic PDAC. Derived immune cells underwent paired single-cell RNA and TCR sequencing. Immune composition, cell-type functional profiles, and T cell clonal expansion patterns were evaluated across tissue sites. Results In total, 106,539 immune cells were sequenced, of which 85,748 met criteria for analysis. We identified 32 cell populations, of which seven demonstrated significant enrichment within a particular tissue, highlighting that this workflow possesses the granularity needed for identifying potential future biomarkers. Functional profiling revealed tissue-specific differences in cell phenotypes. This included terminally differentiated exhausted CD8 T cells within the tumor, highly active Tregs within the premetastatic liver and tumor, and M1 versus M2 polarization of liver and tumor macrophage populations, respectively. Within the tumor, expanded Treg clones were uniquely abundant, and while expanded clones could be tracked to the blood and premetastatic liver, many of these mapped back to known viral antigens. Leveraging previously validated gene sets, we show how these can be applied to predict the tumor reactivity of intratumoral T cells using transcriptional signatures. We demonstrated a high degree of concordance between multiple independent signatures and tracked high-priority TCRs within the blood and liver. Conclusion This study demonstrates the feasibility of a platform, which has already been implemented into ongoing clinical protocols, for immune profiling of human PDAC across the sites most relevant to metastatic progression. Future applications of this work can monitor immune populations throughout metastatic progression to build a temporal database of immune phenotypes and track association with clinical outcomes.
format Article
id doaj-art-14c29031d42e428b87cdd01c0436f438
institution Kabale University
issn 1432-0851
language English
publishDate 2025-08-01
publisher Springer
record_format Article
series Cancer Immunology, Immunotherapy
spelling doaj-art-14c29031d42e428b87cdd01c0436f4382025-08-24T11:32:27ZengSpringerCancer Immunology, Immunotherapy1432-08512025-08-0174911610.1007/s00262-025-04146-5A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolutionElishama N. Kanu0Ashley A. Fletcher1Jiayin Bao2Ethan S. Agritelley3Julia Button4Austin M. Eckhoff5Karrie Comatas6Tao Wang7Bin-Jin Hwang8Michael E. Lidsky9Sabino Zani10Dan G. Blazer11Peter J. Allen12Zhicheng Ji13Frank J. Lowery14Sri Krishna15Nicholas D. Klemen16Daniel P. Nussbaum17Erika J. Crosby18Department of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDuke University School of Medicine, Duke UniversityDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Duke UniversitySurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of HealthSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of HealthSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of HealthDepartment of Surgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterAbstract Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by exceedingly high rates of metastatic progression, with the liver representing the most common site of distant spread. Here, we established a platform for multisite immune profiling of human PDAC encompassing the tumor, peripheral circulation, and premetastatic liver, to more comprehensively study how various immune subsets might contribute to patient outcomes. Methods Tumor, liver, and blood samples were obtained from patients undergoing resection for non-metastatic PDAC. Derived immune cells underwent paired single-cell RNA and TCR sequencing. Immune composition, cell-type functional profiles, and T cell clonal expansion patterns were evaluated across tissue sites. Results In total, 106,539 immune cells were sequenced, of which 85,748 met criteria for analysis. We identified 32 cell populations, of which seven demonstrated significant enrichment within a particular tissue, highlighting that this workflow possesses the granularity needed for identifying potential future biomarkers. Functional profiling revealed tissue-specific differences in cell phenotypes. This included terminally differentiated exhausted CD8 T cells within the tumor, highly active Tregs within the premetastatic liver and tumor, and M1 versus M2 polarization of liver and tumor macrophage populations, respectively. Within the tumor, expanded Treg clones were uniquely abundant, and while expanded clones could be tracked to the blood and premetastatic liver, many of these mapped back to known viral antigens. Leveraging previously validated gene sets, we show how these can be applied to predict the tumor reactivity of intratumoral T cells using transcriptional signatures. We demonstrated a high degree of concordance between multiple independent signatures and tracked high-priority TCRs within the blood and liver. Conclusion This study demonstrates the feasibility of a platform, which has already been implemented into ongoing clinical protocols, for immune profiling of human PDAC across the sites most relevant to metastatic progression. Future applications of this work can monitor immune populations throughout metastatic progression to build a temporal database of immune phenotypes and track association with clinical outcomes.https://doi.org/10.1007/s00262-025-04146-5Single cell RNAseqPDACPre-metastatic liverTCRT cell clonality
spellingShingle Elishama N. Kanu
Ashley A. Fletcher
Jiayin Bao
Ethan S. Agritelley
Julia Button
Austin M. Eckhoff
Karrie Comatas
Tao Wang
Bin-Jin Hwang
Michael E. Lidsky
Sabino Zani
Dan G. Blazer
Peter J. Allen
Zhicheng Ji
Frank J. Lowery
Sri Krishna
Nicholas D. Klemen
Daniel P. Nussbaum
Erika J. Crosby
A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution
Cancer Immunology, Immunotherapy
Single cell RNAseq
PDAC
Pre-metastatic liver
TCR
T cell clonality
title A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution
title_full A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution
title_fullStr A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution
title_full_unstemmed A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution
title_short A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution
title_sort platform for multisite immune profiling of premetastatic pancreatic cancer at single cell resolution
topic Single cell RNAseq
PDAC
Pre-metastatic liver
TCR
T cell clonality
url https://doi.org/10.1007/s00262-025-04146-5
work_keys_str_mv AT elishamankanu aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT ashleyafletcher aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT jiayinbao aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT ethansagritelley aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT juliabutton aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT austinmeckhoff aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT karriecomatas aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT taowang aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT binjinhwang aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT michaelelidsky aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT sabinozani aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT dangblazer aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT peterjallen aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT zhichengji aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT frankjlowery aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT srikrishna aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT nicholasdklemen aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT danielpnussbaum aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT erikajcrosby aplatformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT elishamankanu platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT ashleyafletcher platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT jiayinbao platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT ethansagritelley platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT juliabutton platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT austinmeckhoff platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT karriecomatas platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT taowang platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT binjinhwang platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT michaelelidsky platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT sabinozani platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT dangblazer platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT peterjallen platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT zhichengji platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT frankjlowery platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT srikrishna platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT nicholasdklemen platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT danielpnussbaum platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution
AT erikajcrosby platformformultisiteimmuneprofilingofpremetastaticpancreaticcanceratsinglecellresolution